Provided by Tiger Trade Technology Pte. Ltd.

Lexicon Pharmaceuticals

2.30
+0.12005.50%
Post-market: 2.28-0.0200-0.87%19:30 EDT
Volume:3.19M
Turnover:7.30M
Market Cap:1.02B
PE:-14.49
High:2.31
Open:2.19
Low:2.19
Close:2.18
52wk High:2.68
52wk Low:1.03
Shares:444.00M
Float Shares:220.42M
Volume Ratio:1.09
T/O Rate:1.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.1587
EPS(LYR):-0.1387
ROE:-40.21%
ROA:-14.32%
PB:5.85
PE(LYR):-16.59

Loading ...

Quantum BioPharma Receives United States FDA Clearance To Proceed with Lucid-MS Phase 2 Trial in Progressive Multiple Sclerosis:

GlobeNewswire
·
Aug 10

Lexicon Pharmaceuticals (LXRX) Receives a Buy from Piper Sandler

TIPRANKS
·
Aug 07

Lexicon Pharmaceuticals - to Offer up to 1,257,856 Shares of Common Stock Issuable to Selling Stockholders - SEC Filing

THOMSON REUTERS
·
Aug 07

Lexicon Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Earnings Flash (LXRX) Lexicon Pharmaceuticals Posts Q2 Loss $0.07 a Share, vs. FactSet Est of $0.05 Loss

MT Newswires Live
·
Aug 06

Lexicon Pharmaceuticals Posts Q2 Net Loss

Reuters
·
Aug 06

Lexicon Pharmaceuticals Q2 EPS $(0.07) Misses $(0.05) Estimate, Sales $692.000K Miss $3.998M Estimate

Benzinga Earnings
·
Aug 06

Lexicon Q2 FY26 Net Loss Widens to $31.8 Million; Revenue Drops to $0.7 Million

Reuters
·
Aug 06

Lexicon Pharmaceuticals Q2 Basic EPS USD -0.07

THOMSON REUTERS
·
Aug 06

Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates

GlobeNewswire
·
Aug 06

Lexicon Pharmaceuticals Inc Expected to Post a Loss of 5 Cents a Share - Earnings Preview

Reuters
·
Aug 04

Lexicon Pharmaceuticals Inc Expected to Post a Loss of 5 Cents a Share - Earnings Preview

Reuters
·
Jul 31

Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

GlobeNewswire
·
Jul 30

Lexicon Pharmaceuticals: Advancing Cardiometabolic Pipeline and Phase 3 HCM Data Support Unchanged $6 Price Target and Buy Rating

TIPRANKS
·
Jul 27

Lexicon completes enrollment in SONATA-HCM study

TIPRANKS
·
Jul 27

Lexicon Pharmaceuticals Completes Enrollment in Trial of Potential Hypertrophic Cardiomyopathy Treatment

MT Newswires Live
·
Jul 27

Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 Sonata-Hcm Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (Hcm)

Reuters
·
Jul 27

Lexicon Pharmaceuticals - Topline Results for Sonata-HCM Trial Anticipated in Q1 2027

THOMSON REUTERS
·
Jul 27

How Lexicon Pharma’s Expanded Russell Index Footprint Shapes Its Pipeline Narrative for Investors (LXRX)

Simply Wall St.
·
Jul 02

Lexicon presents new sotagliflozin Type 1 diabetes subgroup analysis at ADA 2026 sessions

Reuters
·
Jun 03